Clinical Profile, Treatment and Predictors during the First COVID-19 Wave : A Population-Based Registry Analysis from Castile and Leon Hospitals

The first wave of the COVID-19 pandemic collapsed the hospitals in Castile and Leon (Spain). An analysis of the clinical characteristics, drug therapies and principal outcome predictors in the COVID-19 hospitalized patients from 1 March to 31 May 2020 is presented through a population-based registry study. Hospital stay variables, ventilation mode data and clinical outcomes were observed. In Castile and Leon hospitals, 7307 COVID-19 patients were admitted, with 57.05% being male and a median of 76 years. The mortality rate was 24.43%, with a high incidence of severe acute respiratory syndrome (SARS) (14.03%) and acute kidney injury (AKI) (10.87%). The most used medicines were antibiotics (90.83%), antimalarials (42.63%), steroids (44.37%) and antivirals, such as lopinavir/ritonavir (42.63%). The use of tocilizumab (9.37%) and anti-SIRS (systemic inflammatory response syndrome) medicines (7.34%) were remarkable. Fundamentally, death occurred more likely over 65 years of age (OR: 9.05). In addition, the need for ventilation was associated with a higher probability of death (OR: 3.59), SARS (OR: 5.14) and AKI (OR: 2.31). The drug-use pattern had been modified throughout the COVID-19 first wave. Multiple factors, such as age, gender and the need for mechanical ventilation, were related to the worst evolution prognosis of the disease.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:17

Enthalten in:

International journal of environmental research and public health - 17(2020), 24 vom: 14. Dez.

Sprache:

Englisch

Beteiligte Personen:

Gutiérrez-Abejón, Eduardo [VerfasserIn]
Tamayo, Eduardo [VerfasserIn]
Martín-García, Débora [VerfasserIn]
Álvarez, F Javier [VerfasserIn]
Herrera-Gómez, Francisco [VerfasserIn]

Links:

Volltext

Themen:

Acute kidney injury
COVID-19
Clinical characteristics
Journal Article
Mortality
Research Support, Non-U.S. Gov't
SARS-CoV-2
Severe acute respiratory syndrome
Treatment

Anmerkungen:

Date Completed 23.12.2020

Date Revised 10.11.2023

published: Electronic

Citation Status MEDLINE

doi:

10.3390/ijerph17249360

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM318926083